stockrow
Saturday 7 November 2026
Export AURA’s income statement to Excel — free account
Aura Biosciences, Inc.
AURA Healthcare Biotechnology
- EPS
- −2.13%
- Free cash flow
- −56.3%
Quarter to June 2026, against a year earlier
6.56
0.22
+3.47%
Follow AURA
Alert me
Aura Biosciences, Inc. (AURA) P/E ratio
Aura Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 1.1× (August 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 1.1×
Ten-year median
0.0×
Current reading's percentile
90
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DNA Ginkgo Bioworks Holdings, Inc. compare | n/m |
| SLDB Solid Biosciences Inc. compare | n/m |
| ACHV Achieve Life Sciences, Inc. compare | n/m |
| SGMT Sagimet Biosciences Inc. compare | n/m |
| AURA Aura Biosciences, Inc. | n/m |
| WVE WAVE Life Sciences Ltd. compare | n/m |
| CGEM Cullinan Therapeutics, Inc. compare | n/m |
| ZVRA Zevra Therapeutics, Inc. compare | 9.0× |
| ATTO Attovia Therapeutics, Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)